EP0556197A4 - Prolonging expression of polynucleotides introduced into a cell - Google Patents

Prolonging expression of polynucleotides introduced into a cell

Info

Publication number
EP0556197A4
EP0556197A4 EP19910917379 EP91917379A EP0556197A4 EP 0556197 A4 EP0556197 A4 EP 0556197A4 EP 19910917379 EP19910917379 EP 19910917379 EP 91917379 A EP91917379 A EP 91917379A EP 0556197 A4 EP0556197 A4 EP 0556197A4
Authority
EP
European Patent Office
Prior art keywords
cell
polynucleotides introduced
prolonging
expression
prolonging expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910917379
Other versions
EP0556197A1 (en
Inventor
George Y Wu
Catherine H Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut
Original Assignee
University of Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Connecticut filed Critical University of Connecticut
Publication of EP0556197A1 publication Critical patent/EP0556197A1/en
Publication of EP0556197A4 publication Critical patent/EP0556197A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
EP19910917379 1990-09-25 1991-09-23 Prolonging expression of polynucleotides introduced into a cell Withdrawn EP0556197A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US588013 1984-03-09
US58801390A 1990-09-25 1990-09-25

Publications (2)

Publication Number Publication Date
EP0556197A1 EP0556197A1 (en) 1993-08-25
EP0556197A4 true EP0556197A4 (en) 1994-05-18

Family

ID=24352098

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910917379 Withdrawn EP0556197A4 (en) 1990-09-25 1991-09-23 Prolonging expression of polynucleotides introduced into a cell

Country Status (5)

Country Link
EP (1) EP0556197A4 (en)
JP (1) JPH06503714A (en)
AU (1) AU8628291A (en)
CA (1) CA2092319A1 (en)
WO (1) WO1992005250A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017761A1 (en) * 1990-05-11 1991-11-28 The University Of Connecticut Targeted protection from cytotoxins
ES2154637T3 (en) * 1991-05-14 2001-04-16 Univ Connecticut CONTRIBUTION OF DIRECT GENES THAT CODIFY IMMUNOGENIC PROTEINS.
GB9119762D0 (en) * 1991-09-16 1991-10-30 Filler Aaron G Particulate agents for nmt
DE69334095T2 (en) * 1992-07-17 2007-04-12 Dana-Farber Cancer Institute, Boston Method for intracellular binding of targeted molecules
IL106760A (en) * 1992-08-25 1999-12-31 Miles Inc Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus
US5656609A (en) * 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
CA2159916A1 (en) * 1993-04-05 1994-10-13 Henry C. Chiou Targeted delivery of genes encoding antisense polyribonucleotides
FR2706486B1 (en) * 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Nucleic sequences, vectors containing them, pharmaceutical compositions and therapeutic uses.
US5851829A (en) * 1993-07-16 1998-12-22 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
JPH0889278A (en) * 1994-09-29 1996-04-09 Ajinomoto Co Inc Modified protein for introducing gene and its production
AU4690596A (en) * 1994-12-30 1996-07-24 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
US5744326A (en) * 1996-03-11 1998-04-28 The Immune Response Corporation Use of viral CIS-acting post-transcriptional regulatory sequences to increase expression of intronless genes containing near-consensus splice sites
ATE376062T1 (en) 1997-08-04 2007-11-15 Cell Genesys Inc ENHANCER OF HUMAN GLANDULAR KALLIC CLEANING, VECTORS CONTAINING IT AND METHODS OF ITS USE
GB9907366D0 (en) * 1999-03-30 1999-05-26 Medical Res Council Method for expressing proteins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GEORGE Y. WU ET AL.: "Delivery systems for gene therapy", BIOTHERAPY, vol. 3, no. 1, January 1991 (1991-01-01), DORDRECHT NL, pages 87 - 95 *
GEORGE Y. WU ET AL.: "Receptor-mediated gene delivery in vivo", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 22, 5 August 1991 (1991-08-05), BALTIMORE, MD US, pages 14338 - 14342 *
GY WU ET AL.: "Targeted gene delivery: persistence of foreign gene expression achieved by pharmacological means", AASLD ABSTRACTS OF PAPERS. HEPATOLOGY, vol. 12, no. 4, 1990, pages 871 *
JM WILSON ET AL.: "Targeted gene transfer to hepatocytes in vivo: mechanism(s) of persistent gene expression", AASLD ABSTRACTS OF PAPERS. HEPATOLOGY, vol. 14, no. 4, 1990, pages 922 *
See also references of WO9205250A1 *
WU, G.Y. ET AL.: "Receptor-mediated gene delivery and expression in hepatocytes", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 183, no. 1, July 1990 (1990-07-01), pages 147, XP023838350, DOI: doi:10.1016/0014-2999(90)91416-9 *

Also Published As

Publication number Publication date
CA2092319A1 (en) 1992-03-26
AU8628291A (en) 1992-04-15
WO1992005250A1 (en) 1992-04-02
EP0556197A1 (en) 1993-08-25
JPH06503714A (en) 1994-04-28

Similar Documents

Publication Publication Date Title
GB2223084B (en) A shell
AU103733S (en) Handbag
EP0556197A4 (en) Prolonging expression of polynucleotides introduced into a cell
AU113166S (en) A handbag
GB8910031D0 (en) Shell
AU106495S (en) Carry case
GB9113143D0 (en) Lipstick holder case
GB9014940D0 (en) A suitcase
GB2161788B (en) A cosmetics case
GB8829283D0 (en) A handbag
GB8817480D0 (en) Hydrogen
GB9103358D0 (en) A pellet implantor
GB8911302D0 (en) Novel pharmacological compounds
GB9102779D0 (en) Structure of a briefcase
GB8802969D0 (en) Antistatic vdu shell
GB9013472D0 (en) Apparatus comprising a plurality of electrolytic cells
AU96848S (en) A lipstick
AU104035S (en) A set of extrusions
AU102663S (en) A drain chamber
AU99885S (en) A set of hats
GB9016313D0 (en) A method of extending capacity of roof-racks
AU96972S (en) A revolver
ZA892234B (en) A suitcase
HU900963D0 (en) Narcotizing shell
AU102568S (en) Lipstick case

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19930611

RHK1 Main classification (correction)

Ipc: C12N 15/87

A4 Supplementary search report drawn up and despatched

Effective date: 19940329

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960302